Anti-P-selectin antibodies

US9068001B2 · kind B2 · utility

Assignees

• Selexys Pharmaceuticals, Inc. · US
• Oklahoma Medical Research Foundation · US

Inventors

• Scott Rollins · Monroe, US
• Richard Alvarez · Edmond, US
• Russell P. Rother · Choctaw, US
• Rodger P. McEver · Oklahoma City, US
• Ziad S. Kawar · Oklahoma City, US

Key dates

• Filing date: Aug 5, 2011
• Grant date: Jun 30, 2015
• Expiry date: Aug 5, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.